insights_auto
Pse është ulur DUL 2,24%?
Zhytu më thellëchevron_right
DUL:ETR
Alnylam Pharmaceuticals, Inc.
200,90 €
arrow_downward
-2,24%(-4,60) 1D
13 tet, 5:35:52 m.d., GMT+2 · EUR
search
TĂ« gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për DUL...
Hap
202,60 €
I lartë
202,60 €
I ulët
200,90 €
Kapitalizimi i tregut
29,95Â mld
VĂ«llimi mesatar
39,00
VĂ«llimi
0,00
Maksimumi 52-javor
417,40 €
Minimumi 52-javor
177,10 €
Numri i punonjësve
2 mijë
Hap
202,60 €
I lartë
202,60 €
I ulët
200,90 €
Kapitalizimi i tregut
29,95Â mld
VĂ«llimi mesatar
39,00
VĂ«llimi
0,00
Maksimumi 52-javor
417,40 €
Minimumi 52-javor
177,10 €
Numri i punonjësve
2 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Investing.com Canada
·
12 orë më parë
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
Investing.com
·
2 ditë më parë
Alnylam EVP Bryan Supran sells $398,855 in shares
Simply Wall Street
·
2 ditë më parë
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
The Globe and Mail
·
2 javë më parë
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Profili
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Rreth Alnylam Pharmaceuticals, Inc.